Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Friday. The stock traded as low as $17.09 and last traded at $17.2580, with a volume of 38,880 shares trading hands. The stock had previously closed at $17.77.
Analysts Set New Price Targets
RCUS has been the subject of a number of recent research reports. Morgan Stanley set a $23.00 target price on Arcus Biosciences in a research note on Monday, August 10th. The Goldman Sachs Group reissued a “buy” rating and set a $42.00 price target on shares of Arcus Biosciences in a research report on Friday, August 7th. Wells Fargo & Company upped their price objective on shares of Arcus Biosciences from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Thursday, August 6th. Citigroup raised their price objective on shares of Arcus Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, October 21st. Finally, Wall Street Zen downgraded shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Arcus Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $39.36.
Get Our Latest Analysis on Arcus Biosciences
Arcus Biosciences Stock Down 3.3%
The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -4.73 and a beta of 1.04. The business has a fifty day moving average of $22.87 and a 200 day moving average of $24.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.34 and a quick ratio of 3.34.
Arcus Biosciences (NYSE:RCUS – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.11). The business had revenue of $9.00 million for the quarter, compared to analyst estimates of $7.58 million. Arcus Biosciences had a negative return on equity of 91.65% and a negative net margin of 453.00%. Arcus Biosciences’s revenue was down 65.4% compared to the same quarter last year. During the same period last year, the business earned ($1.27) EPS. As a group, equities analysts predict that Arcus Biosciences, Inc. will post -3.47 earnings per share for the current year.
Insider Activity at Arcus Biosciences
In other news, CAO Alexander Azoy sold 2,827 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the transaction, the chief accounting officer owned 39,581 shares of the company’s stock, valued at $1,187,430. This represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is currently owned by company insiders.
Institutional Trading of Arcus Biosciences
A number of hedge funds and other institutional investors have recently modified their holdings of RCUS. Bank of New York Mellon Corp purchased a new stake in Arcus Biosciences in the 2nd quarter valued at about $16,741,000. Legal & General Group Plc purchased a new position in Arcus Biosciences during the second quarter worth about $5,906,000. BlackRock Inc. purchased a new position in Arcus Biosciences during the second quarter worth about $506,113,000. Corient Private Wealth LP purchased a new position in Arcus Biosciences during the second quarter worth about $1,823,000. Finally, Handelsbanken Fonder AB acquired a new stake in shares of Arcus Biosciences during the second quarter valued at about $1,202,000. 92.89% of the stock is owned by institutional investors and hedge funds.
Arcus Biosciences Company Profile
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth. Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus’s research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.
Further Reading
- Five stocks we like better than Arcus Biosciences
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
